ReviewInsights into imaging2020
Integrative radiogenomics for virtual biopsy and treatment monitoring in ovarian cancer.
Review in Insights into imaging, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 52 citations in OpenAlex.
- Heterogeneity Analyzed by CT-Based Habitat Analysis for Clinical Management of Cancers: A Narrative Review.The Kaohsiung journal of medical sciences · 2026Review
- A multimodal radiomics model to predict disease-free survival in resected non-small cell lung cancer: integrating clinicopathology, dual-energy CT, and deep learning features.Journal of thoracic disease · 2026Article
- Multimodal artificial intelligence and machine learning in oncology: from data integration to precision cancer care.Frontiers in digital health · 2026Review
- AI-driven radiogenomics in gynecologic oncology: from radiological digital biopsy to a new paradigm in precision therapy.Frontiers in oncology · 2026Review
- Radiomics and radiogenomics in ovarian cancer: a review with a focus on ultrasound applications.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Review
- Exploring causal relationships between brain imaging-derived phenotypes and ovarian cancer risk: a bidirectional Mendelian randomization.Journal of ovarian research · 2025Article
- Integrating Radiogenomics and Machine Learning in Musculoskeletal Oncology Care.Diagnostics (Basel, Switzerland) · 2025Review
- Review
- Exploratory Analysis of Radiomics and Pathomics in Uterine Corpus Endometrial Carcinoma.Scientific reports · 2024Article
- Radiology and multi-scale data integration for precision oncology.NPJ precision oncology · 2024Review
- Radioproteomics stratifies molecular response to antifibrotic treatment in pulmonary fibrosis.JCI insight · 2024Article
- Integration of pre-treatment computational radiomics, deep radiomics, and transcriptomics enhances soft-tissue sarcoma patient prognosis.NPJ precision oncology · 2024Article
- A systematic review and meta-analysis of CT and MRI radiomics in ovarian cancer: methodological issues and clinical utility.Insights into imaging · 2023Review
- Article
- Computed tomography-based texture assessment for the differentiation of benign, borderline, and early-stage malignant ovarian neoplasms.The Journal of international medical research · 2023Article
- Radiomic Signatures Associated with CD8Cancers · 2022Review
- Virtual Biopsy: Just an AI Software or a Medical Procedure?Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- ImaGene: a web-based software platform for tumor radiogenomic evaluation and reporting.Bioinformatics advances · 2022Article
- Artificial intelligence and machine learning in cancer imaging.Communications medicine · 2022Review
- Serous borderline ovarian tumours: an extensive review on MR imaging features.The British journal of radiology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 2 countries.
Funding
Abstract
backgroundOvarian cancer survival rates have not changed in the last 20 years. The majority of cases are High-grade serous ovarian carcinomas (HGSOCs), which are typically diagnosed at an advanced stage with multiple metastatic lesions. Taking biopsies of all sites of disease is infeasible, which challenges the implementation of stratification tools based on molecular profiling. MAIN BODY: In this review, we describe how these challenges might be overcome by integrating quantitative features extracted from medical imaging with the analysis of paired genomic profiles, a combined approach called radiogenomics, to generate virtual biopsies. Radiomic studies have been used to model different imaging phenotypes, and some radiomic signatures have been associated with paired molecular profiles to monitor spatiotemporal changes in the heterogeneity of tumours. We describe different strategies to integrate radiogenomic information in a global and local manner, the latter by targeted sampling of tumour habitats, defined as regions with distinct radiomic phenotypes.
conclusionLinking radiomics and biological correlates in a targeted manner could potentially improve the clinical management of ovarian cancer. Radiogenomic signatures could be used to monitor tumours during the course of therapy, offering additional information for clinical decision making. In summary, radiogenomics may pave the way to virtual biopsies and treatment monitoring tools for integrative tumour analysis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.